462 related articles for article (PubMed ID: 27087446)
21. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein.
Dai E; Han L; Liu J; Xie Y; Kroemer G; Klionsky DJ; Zeh HJ; Kang R; Wang J; Tang D
Autophagy; 2020 Nov; 16(11):2069-2083. PubMed ID: 31920150
[No Abstract] [Full Text] [Related]
22. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
[TBL] [Abstract][Full Text] [Related]
23. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
24. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice.
Habbe N; Shi G; Meguid RA; Fendrich V; Esni F; Chen H; Feldmann G; Stoffers DA; Konieczny SF; Leach SD; Maitra A
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18913-8. PubMed ID: 19028870
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions.
Lubeseder-Martellato C; Alexandrow K; Hidalgo-Sastre A; Heid I; Boos SL; Briel T; Schmid RM; Siveke JT
EBioMedicine; 2017 Feb; 15():90-99. PubMed ID: 28057438
[TBL] [Abstract][Full Text] [Related]
26. The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.
Döppler H; Panayiotou R; Reid EM; Maimo W; Bastea L; Storz P
Sci Rep; 2016 Sep; 6():33758. PubMed ID: 27649783
[TBL] [Abstract][Full Text] [Related]
27. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
28. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
29. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
30. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
[TBL] [Abstract][Full Text] [Related]
31. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer.
Cruz VH; Arner EN; Du W; Bremauntz AE; Brekken RA
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938713
[TBL] [Abstract][Full Text] [Related]
32. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
33. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
[TBL] [Abstract][Full Text] [Related]
34. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas.
Vincent DF; Yan KP; Treilleux I; Gay F; Arfi V; Kaniewski B; Marie JC; Lepinasse F; Martel S; Goddard-Leon S; Iovanna JL; Dubus P; Garcia S; Puisieux A; Rimokh R; Bardeesy N; Scoazec JY; Losson R; Bartholin L
PLoS Genet; 2009 Jul; 5(7):e1000575. PubMed ID: 19629168
[TBL] [Abstract][Full Text] [Related]
36. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.
Pylayeva-Gupta Y; Lee KE; Hajdu CH; Miller G; Bar-Sagi D
Cancer Cell; 2012 Jun; 21(6):836-47. PubMed ID: 22698407
[TBL] [Abstract][Full Text] [Related]
38. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
[TBL] [Abstract][Full Text] [Related]
39. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
40. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.
Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D
Cancer Cell; 2013 Mar; 23(3):406-20. PubMed ID: 23453624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]